Lumos Pharma, Inc. (LUMO)

3.5400 -0.0600 (-1.67%) At close: 04:00PM EDT

Lumos Pharma, Inc.

4200 Marathon Boulevard
Suite 200
Austin, TX 78756
United States
512 215 2630
https://lumos-pharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 33

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Richard J. Hawkins	Founder, CEO & Chairman	854.35k	N/A	1949
Dr. John C. McKew Ph.D.	Chief Scientific Officer & President	860.38k	N/A	1964
Ms. Lori D. Lawley CPA	CFO & Principal Accounting Officer	538.23k	N/A	1984
Ms. Lisa Wells Miller	Senior Director of Investor Relations	N/A	N/A	N/A
Mr. Bradley J. Powers J.D.	Chief Compliance Officer & General Counsel	677.08k	N/A	1979
Mr. Aaron Schuchart B.B.A., CPA, M.B.A.	Chief Business Officer	N/A	N/A	1966
Dr. Pisit Pitukcheewanont FAAP, M.D.	Chief Medical Officer	N/A	N/A	N/A
Ms. Alpa Parikh	Senior Vice President of CMC & Supply Management	N/A	N/A	N/A
Mr. Eddie L. Varnado M.B.A.	Corporate Controller	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic fatty liver disease. Lumos Pharma, Inc. is headquartered in Austin, Texas.

Corporate governance

Lumos Pharma, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.